IJPC Seal
Download FREE Sample Issue or Article
LEARN MORE
Subscribe Today
A subscription to IJPC includes a print copy delivered by postal mail and on-line access to electronic PDF copies of your subscribed issues.
Compounding Theme Archive
CANCER, AIDS, and HOSPICE CARE

CANCER, AIDS, and HOSPICE CARE

Permanent storage and easy retrieval of Journal articles and formulations.
  - Includes the full-color, searchable, PDF files of articles and formulations from the Journal.
  - Print Journal articles in color for your research and marketing needs.
  - Eliminate long searches through past issues for articles and formulations.



Only $95.00


(Select Format)
Instant PDF Download
Mailed CD

This archive contains the following articles listed by volume, issue and page number:

CANCER AND AIDS RELATED ARTICLES
Title (Click for Details) Vol/Issue Page
Treatment of Dermatologic Adverse Events Induced by Oncological Treatments Using Compounded Medications Vol. 22 No. 6 446
Hydroxyurea 100 mg/mL in Ora-Plus:Ora-Sweet, Ora-Plus: Ora-Sweet SF, Ora-Blend or Oral-Blend SF Oral Suspensions Vol. 22 No. 6 496
Prolonged In-use Stability of Reconstituted Herceptin in Commercial Intravenous Bags Vol. 22 No. 5 417
Calculations Vol. 22 No. 4 314
Cinacalcet 5-mg/mL in Oral-Plus/Ora-Sweet Suspension Vol. 22 No. 4 318
Antineoplastic Drug Contamination on the Outside of Prepared Infusion Bags Vol. 22 No. 4 345
Rolapitant Injectable Emulsion with Dexamethasone Sodium Phosphate Admixture Vol. 22 No. 3 237
Rolapitant Injectable Emulsion with Palonosetron Hydrochloride Admixture Vol. 22 No. 2 151
Mercaptopurine 50 mg/mL in Ora-Sweet and Ora-Plus Suspension Vol. 22 No. 1 51
Thalidomide 20 mg/mL in Ora-Plus and Ora-Sweet Suspension Vol. 22 No. 1 58
Effects of Compounded Stanford Modified Oral Rinse (MucoLox) on the Survival and Migration of Oral Keratinocytes and Fibroblasts: Implications for Wound Healing Vol. 22 No. 1 60
Compatibility and Stability of VARUBI (Rolapitant) Injectable Emulsion Admixed with Intravenous Palonosetron Hydrochloride Injection and Dexamethasone Sodium Phosphate Injection Vol. 22 No. 1 76
Compatibility and Stability of VARUBI (Rolapitant) Injectable Emulsion Admixed with Intravenous Granisetron Hydrochloride Vol. 22 No. 1 86
Etoposide 20-mg/mL Injection Vol. 21 No. 5 410
Tacrolimus 0.3-mg/mL Ophthalmic Solution Vol. 21 No. 5 416
Chemical Stability of Morphine, Ropivacaine, and Ziconotide in Combination for Intrathecal Analgesia Vol. 21 No. 4 347
Azathioprine 10-mg/mL Oral Suspension Vol. 21 No. 2 146
Calculations Vol. 21 No. 1 58
Compatibility and Stability of Rolapitant Injectable Emulsion Admixed with Dexamethasone Sodium Phosphate Vol. 21 No. 1 66
Compatibility and Stability of Rolapitant Injectable Emulsion Admixed with Intravenous Palonosetron Hydrochloride Vol. 21 No. 1 76
Erlotinib 10-mg/mL Oral Suspension Vol. 20 No. 6 508
Imatinib 40-mg/mL Oral Suspension Vol. 20 No. 6 510
Lapatinib Ditosylate 50-mg/mL Oral Suspension Vol. 20 No. 6 511
Calculations Vol. 20 No. 5 405
Tretinoin 10-mg Oral Capsules Vol. 20 No. 4 327
Carboplatin 50-mg/mL Injection Vol. 20 No. 3 226
Aprepitant 80-mg Capsules Vol. 20 No. 1 48
Evaluation of the Stability of Mercaptopurine Suspension Compounded in a Commercial Vehicle and the Determination of an Appropriate Beyond-use Date Vol. 20 No. 1 81
Calculations Vol. 19 No. 6 502
Cytarabine 50-mg/mL Injection Vol. 19 No. 4 328
Tacrolimus Capsules, 0.5 mg, 1 mg, or 5 mg Vol. 19 No. 4 333
Stability of Diphenhydramine Hydrochloride, Lorazepam, and Dexamethasone Sodium Phosphate in 0.9% Sodium Chloride Stored in Polypropylene Syringes Vol. 19 No. 4 344
Physico-chemical Stability of MabThera Drug-product Solution for Subcutaneous Injection under In-use Conditions with Different Administration Materials Vol. 19 No. 3 261
Cisplatin 1-mg/mL Injection Vol. 19 No. 1 62
Daunorubicin 5-mg/mL Injection Vol. 19 No. 1 63
Physicochemical and Microbiological Stability of Azathioprine in InOrpha Suspending Agent Studied Under Various Conditions Vol. 19 No. 1 73
Leucovorin 10-mg/mL Injection Vol. 18 No. 6 497
High-Performance Liquid Chromatographic Method Optimization for Ondansetron Assay in Extemporaneous Topical Gel and in Marketed Products Vol. 18 No. 6 520
Roboticized Compounding of Oncology Drugs in a Hospital Pharmacy Vol. 18 No. 5 358
Denileukin Diftitox 150-mcg/mL Injection Vol. 18 No. 4 328
Methotrexate 2.5-mg Capsules Vol. 18 No. 3 238
Tamoxifen 10-mg or 20-mg Capsules Vol. 18 No. 3 240
Fludarabine Phosphate 25-mg/mL Injection Vol. 18 No. 2 143
Secretin 4 mcg/mL Injection Vol. 18 No. 2 148
Lomustine 100-mg Capsules Vol. 18 No. 1 63
Disguising the Taste of Antiretrovirals for Pediatric Patients Infected with Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome: Creative Flavor Compounding and Techniques, Part 2 Vol. 17 No. 6 446
Metyrosine 250-mg Capsules Vol. 17 No. 6 506
Disguising the Taste of Antiretrovirals for Pediatric Patients Infected with Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome: Creative Flavor Compounding and Techniques, Part 1 Vol. 17 No. 5 388
Fluorouracil 50-mg/mL Injection Vol. 17 No. 5 417
Mesna 100-mg/mL Injection Vol. 17 No. 5 420
Methotrexate 25-mg/mL Injection Vol. 17 No. 5 421
Dacarbazine 200-mg/mL Injection Vol. 17 No. 4 330
Mercaptopurine 75-mg Capsules Vol. 17 No. 3 234
PostScription: The Pharmacist's Role in the Treatment of Cancer: A Personal Plea and Testimonial Vol. 17 No. 3 262
Dexrazoxane 1-mg/mL Injection Vol. 17 No. 2 149
Paclitaxel 6-mg/mL Injection Vol. 17 No. 2 151
Thiotepa 15-mg/mL Injection Vol. 17 No. 2 152
Granisetron 1-mg/mL Injection Vol. 17 No. 1 66
Octreotide 50-mcg/mL Injection Vol. 17 No. 1 72
Testosterone Cypionate 100-mg/mL Injection Vol. 17 No. 1 73
Calculations Vol. 16 No. 6 498
Use of a Closed-system Drug Transfer Device (PhaSeal) and Impact on Preparation Time Vol. 16 No. 5 431
Compounding of Slow-release Niacinamide Capsules: Feasibility and Characterization Vol. 16 No. 5 434
Ondansetron Hydrochloride 2-mg/mL Injection Vol. 16 No. 4 339
Gastrointestinal Mucositis: Focus on the Treatment of the Effects of Chemotherapy and Radiotherapy on the Rectum Vol. 16 No. 2 117
Stability of Carboplatin, Paclitaxel, and Docetaxel with Acetyl-L-carnitine During Simulated Y-site Administration Vol. 16 No. 1 82
Oral Mucositis: Etiology and Clinical and Pharmaceutical Management Vol. 16 No. 1 22
Infantile Hemangiomas, Part 2: Topical Treatment with Beta Blockers Vol. 15 No. 6 458
Thioguanine 20-mg/mL Oral Suspension Vol. 15 No. 6 506
Morphine 6-mg/mL, Haloperidol 0.5-mg/mL, and Hyoscine 6-mg/mL Infusion Vol. 15 No. 6 504
Physiochemical Stability of Diluted Trastuzumab Infusion Solutions in Polypropylene Infusion Bags Vol. 15 No. 6 515
Granisetron Hydrochloride 0.2-mg/mL Oral Suspension Vol. 15 No. 5 419
Study of Microbiological Safety of 25 Oncology Drugs After Multiple Uses in Aseptic Conditions Vol. 15 No. 5 428
Methylprednisolone 4-mg/mL Oral Suspension Vol. 15 No. 4 340
Panitumumab 2.5-mg/mL in 0.9% Sodium Chloride Injection Vol. 14 No. 5 428
Potential Treatments for Radiation Dermatitis Vol. 14 No. 3 210
Cyclophosphamide 10-mg/mL Oral Suspension Vol. 14 No. 3 245
Sunitinib 10-mg/mL Oral Suspension Vol. 14 No. 3 248
Hormonal Influences in Prostate Cancer: An Update of a Complex Subject Vol. 14 No. 2 100
Developing a Tretinoin Oral Liquid for Patients Who Cannot Take Capsules Vol. 14 No. 2 118
Mechlorethamine Hydrochloride 0.02% Topical Vol. 13 No. 5 434
Myristyl Nicotinate 5% Topical Gel Vol. 13 No. 5 435
Aprepitant 20-mg/mL Oral Liquid Vol. 13 No. 2 153
Doxorubicin Hydrochloride 1-mg/mL in Sodium Chloride Solution Intravesical Instillation Vol. 13 No. 2 155
Ionic Hydration Solution for Anti-Cancer Therapy Vol. 13 No. 2 156
Compounding for Cancer in Companion Animals Vol. 13 No. 1 42
Compatibility and Stability of Palonosetron Hydrochloride with Lactated Ringer's, Hetastarch in Lactated Electrolyte, and Mannitol Injections During Simulated Y-Site Administration Vol. 12 No. 5 460
Compounding Challenges for Immunocompromised Patients Vol. 12 No. 6 482
Tretinoin and Dexpanthenol Gel Vol. 12 No. 4 361
Physical and Chemical Stability of Palonosetron Hydrochloride with Glycopyrrolate and Neostigmine During Simulated Y-Site Administration Vol. 12 No. 4 368
Cancer-Related Terminology: Glossaries for Compounding Pharmacists and Their Clients Vol. 12 No. 1 16
Hospice and Compounding Pharmacy: Once Inseperable Vol. 12 No. 1 28
Calculations: Compounding for Cancer Patients Vol. 12 No. 1 62
Temozolomide 10-mg/mL Oral Liquid Vol. 11 No. 4 336
Levorphanol for Excruciating Pain from Oral Cancer: A Case Report Vol. 11 No. 3 212
Busulfan 2-mg/mL Oral Liquid Vol. 11 No. 2 155
Ondansetron Hydrochloride 0.8mg/mL Oral Liquid Vol. 11 No. 2 158
Phenoxybenzamine Hydrochloride 2-mg/mL Oral Liquid Vol. 11 No. 2 160
Principles of Pediatric Palliative Care and Pain Control Vol. 11 No. 1 10
Physical and Chemical Stability of Palonosetron with Metoclopramide and Promethazine During Simulated Y-Site Administration Vol. 11 No. 1 82
Cyclophosphamide 2-mg/mL Oral Liquid Vol. 10 No. 6 454
Dermatological Effects from Years in the Sun: Compounding Opportunities Vol. 10 No. 5 336
Hydroxyurea 100 mg/mL Vol. 10 No. 5 384
Indinavir 10-mg/mL Oral Liquid Vol. 10 No. 5 385
Temozolomide Stability in Extemporaneously Compounded Oral Suspensions Vol. 10 No. 5 396
Rifabutin 20-mg/mL Oral Liquid Vol. 10 No. 4 305
Granisetron 0.05-mg/mL Oral Suspension Vol. 10 No. 3 222
Mesna 20-mg/mL Syrup Vol. 10 No. 3 224
Physical and Chemical Stability of Palonosetron Hydrochloride with Dacarbazine and with Methylprednisolone Sodium Succinate During Simulated Y-Site Administration Vol. 10 No. 3 234
Chlorambucil 2-mg/mL Oral Liquid Vol. 10 No. 1 59
Efavirenz 20-mg/mL Oral Liquid, Anhydrous Vol. 10 No. 1 62
Mercaptopurine 50-mg/mL Oral Liquid Vol. 10 No. 1 64
Thioguanine 40-mg/mL Oral Liquid Vol. 10 No. 1 68
Dolasetron 10-mg/mL Oral Liquid Vol. 9 No. 6 475
Brompton's Mixture Vol. 9 No. 4 312
Physical and Chemical Stability of Palonosetron Hydrochloride with Fluorouracil and with Gemcitabine Hydrochloride during Simulated Y-site Administration Vol. 9 No. 4 320
Compounding Antiangiogenic Cancer Therapy for Animals Vol. 9 No. 3 195
Piroxicam 2-mg/mL Oral Liquid, Veterinary Vol. 9 No. 3 234
Physical and Chemical Stability of Palonosetron Hydrochloride with Lorazepam and Midazolam Hydrochloride during Simulated Y-Site Administration Vol. 9 No. 3 235
Physical and Chemical Stability of Palonosetron Hydrochloride with Topotecan Hydrochloride and Irinotecan Hydrochloride during Simulated Y-Site Administration Vol. 9 No. 3 238
Book and Literature Reviews Vol. 8 No. 5 324
Acyclovir 5% and Chlorhexidine Diacetate 0.2% Topical Gel Vol. 8 No. 5 383
Book and Literature Reviews Vol. 8 No. 4 244
Diphenhydramine HCl 0.1%, Lidocaine HCl 1%, Misoprostol 0.0024% and Triamcinolone Acetonide 0.12% Oral Rinse Vol. 8 No. 4 296
Glycopyrrolate 0.5-mg/mL Oral Liquid Vol. 8 No. 3 218
Stomatitis Mouthwash Vol. 8 No. 2 140
Tacrolimus 0.5-mg/mL Oral Liquid Vol. 8 No. 2 141
Stability of Oral Liquid Dosage Forms of Glycopyrrolate Prepared with the Use of Powder Vol. 7 No. 5 386
ABHR in PLO (Lorazepam, Diphenhydramine HCl, Haloperidol, Metoclopramide HCl) Vol. 7 No. 3 183
The Hormonal Link to Breast Cancer: The Estrogen Matrix Vol. 6 No. 4 250
Sterilization of Talc for Use in Pleurodesis Vol. 6 No. 2 140
Antineoplastic Agents Vol. 5 No. 4 268
A New High-Performance Liquid Chromatographic Method for Fludarabine and Fludarabine Phosphate Compounded in Liposomes Vol. 5 No. 4 320
Mitomycin 0.02% Ophthalmic Solution Vol. 5 No. 3 209
Promethazine HCl 50-mg/mL in PLO Gel Vol. 5 No. 1 51
Human Immunodeficiency Virus and the Acquired Immune Deficiency Syndrome Vol. 4 No. 5 334
Hospice and the Role of the Compounding Pharmacist Vol. 4 No. 4 246
Nausea and Vomiting in Hospice Patients Vol. 4 No. 4 250
Ketamine for Pain in Hospice Patients Vol. 4 No. 4 253
Custom-Making Medications for the Hospice Patient Vol. 4 No. 4 255
Surviving Cancer - How the Compounding Pharmacist Can Help Vol. 4 No. 4 257
Providing Positive Outcomes through Compounding for Animal Cancer Patients Vol. 4 No. 4 264
Dacarbazine 8-mg/mL, Doxorubicin HCl 0.8-mg/mL and Ondansetron 0.64-mg/mL injection Vol. 4 No. 4 296
Dexamethasone 1.2%, Lorazepam 0.1%, Haloperidol 0.1%, Diphenhydramine HCl 2.4% and Metoclopramide HCl 2.4% in PLO Vol. 4 No. 4 297
Doxorubicin HCl 0.4-mg/mL, Ondansetron HCl 0.48-mg/mL and Vincristine Sulfate 14-mcg/mL Injection Vol. 4 No. 4 298
Misoprostol 0.0024% Mouth Rinse for Oral Ulcerations Vol. 4 No. 4 302
Ondansetron HCl 8-mg/mL in PLO Vol. 4 No. 4 305
Stability of 5-Fluorouracil in an Extemporaneously Compounded Ophthalmic Solution Vol. 4 No. 4 320
Tamoxifen Citrate - A Potential Therapy for the Treatment of Keloids Vol. 3 No. 5 380
Tamoxifen Citrate Cream 0.1% Vol. 3 No. 5 381
Compatibility of Docetaxel with Selected Drugs during Simulated Y-Site Administration Vol. 3 No. 3 241
Oral Ulceration Mouthwash Vol. 3 No. 1 10
Five-Day Stability of Vinorelbine in 5% Dextrose Injection and in 0.9% Sodium Chloride Injection at Room Temperature Vol. 3 No. 1 67
Minimizing the Risk of Teratogenic Substance Exposure for Pregnant Compounding Pharmacists Vol. 2 No. 6 414
Compatibility of Paclitaxel Injection Diluent with Two Reduced-Phthalate Administration Sets for the Acclaim Pump Vol. 2 No. 5 382
Fluorouracil 5% Topical Stick Vol. 2 No. 4 300
Paclitaxel Compatibility with IV Express Filter Unit Vol. 2 No. 3 243
Estrogen and Breast Cancer: Is There a Link? Vol. 2 No. 1 21
Ondansetron Suppositories: Extemporaneous Preparation, Drug Release, Stability and Flux through Rabbit Rectal Membrane Vol. 2 No. 1 83
Stability of Mechlorethamine Hydrochloride 0.01% Ointment in Aquaphor® Base Vol. 2 No. 1 89
Compounding Pharmacists Play a Vital Role in AIDS Treatment Vol. 1 No. 6 386
Doxorubicin HCl-Vincristine Sulfate Injection Vol. 1 No. 5 324
Granisetron HCl-Dexamethasone Sodium Phosphate Injection Vol. 1 No. 5 326
Metoclopramide-Lorazepam-Mannitol-Prochlorperazine Antiemetic Injection Vol. 1 No. 5 328
Ondansetron HCl-Dexamethasone Sodium Phosphate Injection Vol. 1 No. 5 332
Ondansetron HCl-Doxorubicin HCl-Dacarbazine Injection Vol. 1 No. 5 333
Ondansetron HCl-Doxorubicin Sulfate-Vincristine Sulfate Injection (2 concentrations) Vol. 1 No. 5 334
Stability of Mitomycin Aqueous Solution When Stored in Tuberculin Syringes Vol. 1 No. 4 282
Antiemetic Injection for Cancer Chemotherapy Vol. 1 No. 3 175
Rectal and Stomal Administration of Analgesic Suppositories Vol. 1 No. 1 12
Aromatherapy and the Hospice Patient Vol. 1 No. 1 18
ABH Hard Troche Vol. 1 No. 1 26
ABH Soft Troche Vol. 1 No. 1 27
ABH Sugar Troche Vol. 1 No. 1 27
Antiemetic Suppositories of the Gralla Type Vol. 1 No. 1 28
Metoclophen Nausea Suppositories Vol. 1 No. 1 31
Metoclophen-Modified Nausea Suppositories Vol. 1 No. 1 31
Ondansetron HCl Suppositories Vol. 1 No. 1 34
Scopolamine Hydrobromide 0.4-mg/0.1-mL Nasal Solution Vol. 1 No. 1 37
Scopolamine Hydrobromide 0.25-mg/0.1-mL Topical Gel Vol. 1 No. 1 38
Compounding an Extended Stability Admixture of Paclitaxel for Long-Term Infusion Vol. 1 No. 1 49

HOSPICE/PALLIATIVE CARE RELATED ARTICLES
Title (Click for Details) Vol/Issue Page
Compounded Drugs of Value in Outpatient Hospice and Palliative Care Practice Vol. 18 No. 3 190
Palliative Care and Compounding for Household Pets Vol. 16 No. 6 452
Compounded Oral Ketamine for Severe Depression, Anxiety, and Pain in a Hospice Patient with End-stage Chronic Obstructive Pulmonary Disease, Cardiopulmonary Failure, and Severe Renal Insufficiency: A Case Report Vol. 16 No. 5 364
When Traditional Medicine Fails Vol. 14 No. 1 6
Compounding for Cancer in Companion Animals Vol. 13 No. 1 42
Topical Treatment of Neuropathic Pain Vol. 12 No. 3 182
Hospice and Compounding Pharmacy: Once Inseperable Vol. 12 No. 1 28
Principles of Pediatric Palliative Care and Pain Control Vol. 11 No. 1 10
Hospice Symptom Relief Kit: An Update Vol. 10 No. 4 288
Aseptic Compounding in New Zealand and the Use of Still Air Boxes Vol. 10 No. 4 293
Initial Selection of Antiemetics in End-of-Life Care: A Retrospective Analysis Vol. 10 No. 2 147
Hospice from a Compounding Pharmacist's Perspective Vol. 10 No. 2 89
ABHR Gel in the Treatment of Nausea and Vomiting in the Hospice Patient Vol. 10 No. 2 95
The Story of Hospice Vol. 10 No. 2 100
The Dying Process Vol. 10 No. 2 103
Current Topical Treatments in Wound Healing - Part 1 Vol. 8 No. 4 269
Scopolamine Hydrobromide 0.25-mg/0.1-mL Topical Gel Vol. 8 No. 3 185
Indomethacin 50-mg Suppositories Vol. 7 No. 5 375
ABHR in PLO (Lorazepam, Diphenhydramine HCl, Haloperidol, Metoclopramide HCl) Vol. 7 No. 3 183
Hospice and the Role of the Compounding Pharmacist Vol. 4 No. 4 246
Nausea and Vomiting in Hospice Patients Vol. 4 No. 4 250
Ketamine for Pain in Hospice Patients Vol. 4 No. 4 253
Custom-Making Medications for the Hospice Patient Vol. 4 No. 4 255
Basics of Compounding: Compounding Suppositories: Part I - Theoretical Considerations Vol. 4 No. 4 289
Dexamethasone 1.2%, Lorazepam 0.1%, Haloperidol 0.1%, Diphenhydramine HCl 2.4% and Metoclopramide HCl 2.4% in PLO Vol. 4 No. 4 297
Managing Pain in the Terminally Ill Vol. 2 No. 2 111
The Symptom Relief Kit for Hospice Patients Vol. 2 No. 2 116
Compounding Pharmacists Play a Vital Role in AIDS Treatment Vol. 1 No. 6 386
Hospice Care and the Pharmacist Vol. 1 No. 1 11
Rectal and Stomal Administration of Analgesic Suppositories Vol. 1 No. 1 12
Aromatherapy and the Hospice Patient Vol. 1 No. 1 18
Aromatherapy Mood Elevation No. 1 Vol. 1 No. 1 20
Aromatherapy Mood Elevation No. 2 Vol. 1 No. 1 21
ABH Hard Troche Vol. 1 No. 1 26
ABH Soft Troche Vol. 1 No. 1 27
ABH Sugar Troche Vol. 1 No. 1 27
Morphine Sulfate Slow-Release Suppositories Vol. 1 No. 1 32
Ondansetron HCl Suppositories Vol. 1 No. 1 34
Morphine Suppositories Vol. 1 No. 1 36